BRAF and non-small cell lung carcinoma: In addition, dabrafenib is a well-known inhibitor of B-Raf, which suppresses the downstream Ras/Raf/ERK/MAPK pathway (Spagnolo et al., 2014), which has been approved for clinical use for the treatment of non-small cell lung cancer expressing B-Raf V600E mutations and in melanoma (Odogwu et al., 2018).